Tyr352 as a Predominant Phosphosite in the Understudied Kinase and Molecular Target, HIPK1: Implications for Cancer Therapy
OMICS: A Journal of Integrative Biology · 2024-03 · 28 (3) · 111-124
DOI: 10.1089/omi.2023.0244 ↗Kurz gefasst
Fachartikel in der Zeitschrift OMICS: A Journal of Integrative Biology, online erschienen am 25.03.2024. Verfasst von Diya Sanjeev und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Integrative Omics Data Science (CIODS), Yenepoya (Deemed-to-be University), Mangalore, Karnataka, India. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
Homeodomain-interacting protein kinase 1 (HIPK1) is majorly found in the nucleoplasm. HIPK1 is associated with cell proliferation, tumor necrosis factor-mediated cellular apoptosis, transcription regulation, and DNA damage response, and thought to play significant roles in health and common diseases such as cancer. Despite this, HIPK1 remains an understudied molecular target. In the present study, based on a systematic screening and mapping approach, we assembled 424 qualitative and 44 quantitative phosphoproteome datasets with 15 phosphosites in HIPK1 reported across multiple studies. These HIPK1 phosphosites were not currently attributed to any functions. Among them, Tyr352 within the kinase domain was identified as the predominant phosphosite modulated in 22 differential datasets. To analyze the functional association of HIPK1 Tyr352, we first employed a stringent criterion to derive its positively and negatively correlated protein phosphosites. Subsequently, we categorized the correlated phosphosites in known interactors, known/predicted kinases, and substrates of HIPK1, for their prioritized validation. Bioinformatics analysis identified their significant association with biological processes such as the regulation of RNA splicing, DNA-templated transcription, and cellular metabolic processes. HIPK1 Tyr352 was also identified to be upregulated in Her2+ cell lines and a subset of pancreatic and cholangiocarcinoma tissues. These data and the systems biology approach undertaken in the present study serve as a platform to explore the functional role of other phosphosites in HIPK1, and by extension, inform cancer drug discovery and oncotherapy innovation. In all, this study highlights the comprehensive phosphosite map of HIPK1 kinase and the first of its kind phosphosite-centric analysis of HIPK1 kinase based on global-level phosphoproteomics datasets derived from human cellular differential experiments across distinct experimental conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Integrative Omics Data Science (CIODS), Yenepoya (Deemed-to-be University), Mangalore, Karnataka, India.
ORCID-Profile: Rajesh Raju
Zitieren
APA
Sanjeev, D., George, M., John, L., Gopalakrishnan, A. P., Priyanka, P., Mendon, S., Yandigeri, T., Nisar, M., Nisar, M., Kanekar, S., Balaya, R. D. A., & Raju, R. (2024). Tyr352 as a Predominant Phosphosite in the Understudied Kinase and Molecular Target, HIPK1: Implications for Cancer Therapy. OMICS: A Journal of Integrative Biology, 28(3), 111-124. https://doi.org/10.1089/omi.2023.0244
Vancouver
Sanjeev D, George M, John L, Gopalakrishnan AP, Priyanka P, Mendon S, et al. Tyr352 as a Predominant Phosphosite in the Understudied Kinase and Molecular Target, HIPK1: Implications for Cancer Therapy. OMICS: A Journal of Integrative Biology. 2024;28(3):111-124. doi:10.1089/omi.2023.0244
BibTeX
@article{Sanjeev2024,
author = {Sanjeev, Diya and George, Mejo and John, Levin and Gopalakrishnan, Athira Perunelly and Priyanka, Pahal and Mendon, Spoorthi and Yandigeri, Tanuja and Nisar, Mahammad and Nisar, Muhammad and Kanekar, Saptami and Balaya, Rex Devasahayam Arokia and Raju, Rajesh},
title = {Tyr352 as a Predominant Phosphosite in the Understudied Kinase and Molecular Target, HIPK1: Implications for Cancer Therapy},
journal = {OMICS: A Journal of Integrative Biology},
year = {2024},
volume = {28},
number = {3},
pages = {111--124},
doi = {10.1089/omi.2023.0244}
}
EUVIMED